Skip to main content
SpringerLink
Log in

Hydralazine for Chronic Heart Failure

  • Chapter
Acute and Chronic Heart Failure

  • 96 Accesses

Abstract

For more than 30 years, hydralazine has been known as an antihypertensive agent. Its therapeutic spectrum was relatively broad until the occurrence of major side effects became known. Dose reduction and combination with diuretics or beta-adrenergic receptor blocking agents led to a renewed increase in its use for the management of hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature

  • Chatterjee K, Parmley WW, Swan HJC, Berman G, Forrester J, Marcus HS (1973) Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvular apparatus. Circulation 48: 684–690

    PubMed  CAS  Google Scholar 

  • Chatterjee K, Drew D, Parmley WW, Klausner SC, Polansky J, Zacherle B (1976 a) Combination vasodilator therapy for severe chronic congestive heart failure. Ann Intern Med 85: 467–470

    CAS  Google Scholar 

  • Chatterjee K, Parmley WW, Massie B, Greenberg B, Werner J, Klausner S, Norman A (1976 b) Oral hydralazine therapy for chronic refractory heart failure. Circulation 54: 879–883

    CAS  Google Scholar 

  • Chatterjee K, Parmley WW (1977) The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 19: 301

    Article  PubMed  CAS  Google Scholar 

  • Chatterjee K, Brundage B, Parmley W (1979) Oral hydralazine-pharmacology and clinical applications in chronic heart failure. In: Gould L, Reddy CVR (eds) Vasodilator therapy for cardiac disorders. Futura, Mount Kisco, New York, pp 179–208

    Google Scholar 

  • Chatterjee K, Ports T, Brundage B, Massie B, Holly AN, Parmley WW (1980) Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects. Ann Intern Med 92: 600–604

    PubMed  CAS  Google Scholar 

  • Cogan J, Humphreys M, Carlson J, Rapaport E (1979) Afterload reduction increases renal blood flow and maintains glomerular filtration rate in patients with congestive heart failure (Abstract). Clin Res 27: 3 A

    Google Scholar 

  • Franciosa J A, Pierpont G, Cohn JN (1977) Hemodynamic improvement after oral hydralazine in left ventricular failure. A comparison with nitroprusside infusion in 16 patients. Ann Intern Med 86: 388–393

    PubMed  CAS  Google Scholar 

  • Franciosa JA, Weber KT, Kinasewitz GT, West J W, Cohn JN (1980) Long-term hydralazine versus placebo therapy of chronic heart failure ( Abstract ). Circulation [Suppl III] 62: 994

    Google Scholar 

  • Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K (1978) Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 58: 273–279

    PubMed  CAS  Google Scholar 

  • Greenberg BH, DeMots H, Murphy E, Rahimtoola SH (1980) Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency. Circulation 62: 49–55

    PubMed  CAS  Google Scholar 

  • Greenberg BH, DeMots H, Murphy E, Rahimtoola SH (1982) Arterial dilators in mitral regurgitation: effects on rest and exercise hemodynamics and long-term clinical follow-up. Circulation 65: 181–187

    Article  PubMed  CAS  Google Scholar 

  • Judson WE, Hollander W, Wilkins RW (1956) The effects of intravenous ApresolineR (hydralazine) and cardiovascular and renal functions in patients with and without congestive heart failure. Circulation 13: 664–674

    PubMed  Google Scholar 

  • Khatri I, Vemura N, Notargiacomo A, Freis ED (1977) Direct and reflex cardiostimulating effects of hydralazine. Am J Cardiol 40: 38–42

    Article  Google Scholar 

  • Kment A (1981) Vasodilatatoren bei normotensiver und hypertensiver Herzinsuffizienz. Intern Welt 4: 497–504

    Google Scholar 

  • Kment A, Klepzig M, Büll U, Strauer BE (1980) Koronare Hämodynamik und myokardialer Sauerstoffverbrauch unter Dihydralazininfusionen. Verh Dtsch Ges Inn Med 86: 633–639

    Google Scholar 

  • Koch-Weser J (1976) Drug therapy: hydralazine. N Engl J Med 295: 320–323

    Article  PubMed  CAS  Google Scholar 

  • Leier CV, Desch CE, Magorien RD, Triffon DW, Unverferth DV, Boudoulas H, Lewis RP (1980) Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. Am J Cardiol 46: 1039–1044

    Article  PubMed  CAS  Google Scholar 

  • Leier CV, Magorien RD, Desch CE, Thompson MJ, Unverferth DV (1981) Hydralazine and isosorbide dinitrate: comparative central and regional hemodynamic effects when administered alone or in combination. Circulation 63: 102–109

    Article  PubMed  CAS  Google Scholar 

  • Magorien RD, Brown GP, Unverferth DV, Nelson S, Boudoulas H, Bambach D, Leier CV (1982) Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure. Circulation 65: 528–533

    Article  PubMed  CAS  Google Scholar 

  • Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW (1977) Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol 40: 794–801

    Article  PubMed  CAS  Google Scholar 

  • Massie B, Ports T, Chatterjee K, Parmley WW, Ostland J, O’Young J, Haughom F (1981 a) Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63: 269–278

    Article  CAS  Google Scholar 

  • Massie B, Kramer B, Haughom F (1981b) Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation 63: 658–664

    Article  PubMed  CAS  Google Scholar 

  • Massie BM, Kramer B, Haughom F (1981 c) Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation 64: 1218–1226

    Google Scholar 

  • Mathey DG (1983) The use of hydralazine for chronic cardiac failure: results and unanswered questions. In: Just H, Bussmann WD (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 131–138

    Chapter  Google Scholar 

  • Mathey DG, Hanrath P, Polster J, Witte G, Montz R, Bleifeld W (1980) Acute and chronic effects of oral hydralazine on left ventricular pump function and renal hemodynamics in chronic left heart failure. Eur Heart J 1: 25–29

    PubMed  CAS  Google Scholar 

  • McMahon FG (1978) Management of essential hypertension, chapt. VIII. Futura, Mount Kisco New York, p 233

    Google Scholar 

  • Morand P, Lavigne G (1983) The long-term effects of dihydralazine and hydralazine on intractable cardiac failure. In: Just H, Bussmann WD (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 124–130

    Chapter  Google Scholar 

  • Morrow JD, Schroeder HA, Perry HM Jr (1953) Studies in the control of hypertension by hyphex. II. Toxic reaction and side effects. Circulation 8: 829

    PubMed  CAS  Google Scholar 

  • Packer M, Meiler J, Medina N, Gorlin R, Herman MV (1980) Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. N Engl J Med 303: 250–254

    Article  PubMed  CAS  Google Scholar 

  • Reifart N, Bunge T, Kaltenbach M, Bussmann WD (1982) Akute Wirkung und Langzeittherapie mit Dihydralazin in Ruhe und unter Belastung bei schwerer chronischer Herzinsuffizienz. Z Kardiol 71: 75–81

    PubMed  CAS  Google Scholar 

  • Rubin SA, Chatterjee K, Parmley WW (1980) Metabolie assessment of exercise in chronic heart failure patients treated with short-term vasodilators. Circulation 61: 543–548

    PubMed  CAS  Google Scholar 

  • Walsh WF, Greenberg BH (1981) Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 64: 499–505

    Article  PubMed  CAS  Google Scholar 

  • Wilson JR, Untereker W, Hirshfeld J (1981) Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure. Am J Cardiol 48: 934–938

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-6000, Frankfurt 70, Germany

    Professor Dr. med. Wulf-Dirk Bussmann

Authors
  1. Professor Dr. med. Wulf-Dirk Bussmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bussmann, WD. (1986). Hydralazine for Chronic Heart Failure. In: Acute and Chronic Heart Failure. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61627-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61627-3_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64890-8

  • Online ISBN: 978-3-642-61627-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation